BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 20, 2026
Home » Topics » Inflammatory, BioWorld Science

Inflammatory, BioWorld Science
Inflammatory, BioWorld Science RSS Feed RSS

Scientific figure illustrating astrocytes and neuron synapse
Neurology/Psychiatric

Glial cells get all-too-rare star turn at biannual meeting

July 13, 2023
By Anette Breindl
In brain research, be it basic or clinical, neurons have long hogged the limelight. But at the 2023 European Meeting on Glial Cells in Health and Disease, neurons take a back seat to glia – cell types that have often been described as support cells and treated as an afterthought, but that play critical roles in all aspects of brain function, including information processing.
Read More
Inflammatory

Orixa Therapeutics patents new PR3 and ELANE inhibitors

July 12, 2023
Orixa Therapeutics LLC has disclosed small...
Read More
Inflammatory

ADS-032, dual NLRP1 and NLRP3 inflammasome inhibitor with efficacy in models of pulmonary inflammation and infection

July 11, 2023
Researchers from Adiso Therapeutics Inc. have reported the discovery of a novel small-molecule dual NLRP1 and NLRP3 inflammasome inhibitor, ADS-032, being developed for the treatment of inflammatory diseases. Screening of an in-house bioactive compound library led to the discovery of ADS-032, a sulfonylurea compound.
Read More
Close up of senior man holding wrist of arthritic hand
Musculoskeletal

Discovery of novel VEGFR-2 kinase inhibitor with promising antiarthritic and antiangiogenic properties

July 7, 2023
Researchers from Anhui Medical University presented the discovery and preclinical evaluation of new vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitors as potential therapeutic candidates for rheumatoid arthritis.
Read More
Art concept for inflamed human tissue
Inflammatory

New chiral pyrazolo isoquinoline derivatives with promising anti-inflammatory properties reported

July 3, 2023
Natural compounds derived from quinoline and isoquinoline have gained significant attention due to their remarkable biological properties, encompassing antibacterial, anticancer and anti-inflammatory activities. Meanwhile, pyrazoles, a prominent class of heterocyclic compounds, exhibit a wide range of biological and pharmaceutical properties.
Read More
T cells
Inflammatory

ANB-033, a novel anti-human CD122 MAb for T-cell-mediated inflammatory autoimmune disorders

June 29, 2023
CD122 signaling plays a key role in the function of CD4, CD8 T cells and natural killer (NK) cells, as well as in the development and survival of tissue-resident memory T cells (TRMs).
Read More
MRI scan of a fixed cerebral hemisphere from a person with multiple sclerosis
Neurology/Psychiatric

First GWAS for MS severity turns up first brain-related SNP

June 29, 2023
By Anette Breindl
Multiple sclerosis (MS) is and remains “a problem in the immune system” Stephen Sawcer told BioWorld. As in other autoimmune diseases, a faulty immune system attacks otherwise healthy tissues that it should be leaving alone. In the case of MS, the tissue in question is oligodendrocytes. And a study published online in Nature on June 28, 2023, suggests that while MS’ beginnings are autoimmune, the path it takes in an individual patient is determined in part by how well the brain can cope with the autoimmune attack.
Read More
NLRP3 inflammasome
Inflammatory

New mitochondrial players identified in NLRP3 inflammasome activation

June 20, 2023
By Subhasree Nag
The NLRP3 inflammasome is a multiprotein complex that plays a pivotal role in regulating the innate immune system and inflammatory signaling. Upon activation by pathogen-associated molecular patterns (PAMPs), NLRP3 oligomerizes and activates caspase-1 which initiates the processing and release of pro-inflammatory cytokines IL-1β and IL-1 that are overproduced in many inflammatory disease conditions.
Read More
Respiratory

Intraperitoneally or orally administered OLT-1177 improves experimental allergic asthma

June 13, 2023
At the recent EAACI meeting, researchers presented preclinical data for the inflammasome inhibitor OLT-1177 (dapansutrile), which is being evaluated by Olatec Therapeutics LLC for the treatment of inflammatory diseases.
Read More
COVID-19 research illustration
Immune

Neobiosis to advance Vixome for post-COVID syndrome

June 13, 2023
Neobiosis LLC has received FDA clearance of its IND application for Vixome for the treatment of post-COVID syndrome, or long-haul COVID...
Read More
Previous 1 2 … 39 40 41 42 43 44 45 46 47 … 92 93 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing